ClinicalTrials.gg
CompletedNCT07030010Updated May 28, 2026

Effect of a Liquid Tonic Drink on Post-meal Glucose and Insulin Responses

An interventional study of Breakfast meal challenge with tonic drink and Breakfast meal challenge with placebo drink in Overweight or Obese Adults, sponsored by Australian Catholic University. Completed at 1 site in Australia. Open to participants aged 30 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Australian Catholic University · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
30 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 83 studies in Overweight with a site in Australia — 35 open to participants now, 45 under way, 22 of them phase 3. Overweight · Australia.

Enrollment
77th of 79
20 · median 209
Started
2025
with 15 others
No phase
8 of 83
2 open now
Registered
43rd of 83
by date

Among the 83 studies in Overweight with a site in Australia, this one is the 77th largest by enrollment of the 79 interventional ones that give a count, is one of 16 that started in 2025, is one of 8 with no phase, and was the 43rd registered.

Overweight

3,623 studies on the registry are indexed under Overweight; 864 are open to participants now.

Browse Overweight studies →

Open to participants now

35 of the 83 studies in Overweight with a site in Australia are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 538 Overweight studies recruiting now, 163 (30%) set no upper age limit and 348 (65%) stop at 75 or younger; 64 take children under 18; 206 take healthy volunteers.

This study: 30 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Overweight with a site in Australia, or all of them as a file.
02

Study summary

A randomised, double blinded, placebo-controlled crossover design clinical trial conducted at the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with overweight/ obesity. This study will measure the postprandial glucose and hormone responses to a high-carbohydrate meal with/ without a liquid tonic drink.

Read the detailed description

Twenty individuals living with overweight/ obesity will be invited to attend the university laboratories on 2 separate occasions to participate in a postprandial (meal) challenge. Participants will consume the same high-carbohydrate meal on each visit, with or without a liquid tonic drink. This will be a cross-over design study, where participants will consume a placebo drink on the alternate visit. Participants will remain in the laboratory for 3-hours following the meal with a venous cannula in place, and have blood samples taken at regular timepoints. Blood samples will be analysed for glucose and appetite hormones. Participants will also wear a continuous glucose monitor throughout the period which encapsulates both study trials.

03

Conditions studied

  • Overweight or Obese Adults

Browse trials for

Keywords

  • Postprandial hormones
  • Mixed meal challenge
  • Tonic drink
04

Who can participate

Ages eligible
30 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥30-64 years
  • (BMI) of ≥27.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • younger than 30 or 65 years or older,
  • a less than 27.0 kg/m2,
  • have an allergy to any of the components in the plant-based tonic (see section 6),
  • pregnant or breastfeeding,
  • regularly skipping breakfast (i.e. not consuming breakfast on 5/7 days per week),
  • any diagnosed metabolic (e.g. diabetes), endocrine (e.g. hyperthyroidism), gastrointestinal (e.g. Crohn's) or cardiovascular (e.g. heart failure) abnormalities,
  • on an energy-restricted diet; significant weight fluctuation in the previous 3 months (>5% body weight),
  • high alcohol consumption (>14 units/week) (as per Alcohol Drink Guidelines),
  • medication that is used to treat blood glucose,
  • unable to attend in person testing sessions, or
  • unable or unwilling to provide blood samples.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Tonic drink

    This arm will receive the tonic drink on their first postprandial challenge

    Other: Breakfast meal challenge with tonic drink

  • Placebo comparator
    Placebo drink

    This arm will receive the placebo drink on their first postprandial challenge

    Other: Breakfast meal challenge with placebo drink

Interventions

  • OtherBreakfast meal challenge with tonic drink

    High-carbohydrate containing breakfast meal with the addition of the tonic drink

  • OtherBreakfast meal challenge with placebo drink

    High-carbohydrate containing breakfast meal with the addition of the placebo drink

06

What researchers measure

Primary outcomes

  1. 3-hour postprandial glucose incremental area under the curve

    Venous glucose concentrations measured over the 3 hour period following consumption of the breakfast meal and tonic drink/ placebo, and calculated using the trapezoid method, with T0 concentration as baseline

    Time frame: 3 hours

Secondary outcomes

  1. 3-hour postprandial insulin incremental area under the curve

    Venous insulin concentrations measured over the 3 hour period following consumption of the breakfast meal and tonic drink/ placebo, and calculated using the trapezoid method, with T0 concentration as baseline

    Time frame: 3-hours

  2. 3-hour interstitial postprandial glucose incremental area under the curve

    The interstitial glucose levels observed for the 3 hours following consumption of the breakfast meal and tonic drink/placebo using continuous glucose monitors

    Time frame: 3 hours

  3. Matsuda index (Marker of whole-body postprandial insulin sensitivity)

    This marker takes into account the 3- hour postprandial venous blood glucose and insulin measurements observed

    Time frame: 3 hours

  4. Venous blood C-peptide responses

    3-hour postprandial C-peptide responses measured in venous blood as a marker of insulin secretion

    Time frame: 3 hours

  5. Venous blood insulin to glucagon ratio's at baseline (T0) and 30 minutes (T30)

    Ratio of venous blood insulin to glucagon at baseline and 30 minutes (T0, T30) as a marker of hepatic glucose production.

    Time frame: 30 minutes

07

Study locations

1 site
  • Australian Catholic University
    Melbourne, Victoria 3065, Australia
08

References and documents

Individual participant data

Plan to share: Yes — The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.

Supporting information: Study protocol

Access criteria: Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Dec 2025, 5 months.

Of 1,314 non-industry interventional studies with no phase under Overweight, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's 5 months is below that.

Counting every sponsor, half of 1,427 studies reached it within 17 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 19, 2025
StartActual
Jul 8, 2025
Primary completionActual
Dec 19, 2025
CompletionActual
Jan 30, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030010
Lead sponsor
Australian Catholic University
Responsible party
Sponsor
First posted
Jun 19, 2025
Start date
Jul 8, 2025
Primary completion
Dec 19, 2025
Completion
Jan 30, 2026
Last update
May 28, 2026

Study contacts

Leonidas Karagounis, PhD
principal investigator · Australian Catholic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion